NASDAQ:SNNA - Sienna Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.9486 +0.01 (+0.34 %)
(As of 02/19/2019 09:34 AM ET)
Previous Close$2.94
Today's Range$2.94 - $2.9486
52-Week Range$2.05 - $21.53
Volume2,068 shs
Average Volume441,247 shs
Market Capitalization$62.33 million
P/E Ratio-0.57
Dividend YieldN/A
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SNNA



Sales & Book Value

Annual SalesN/A
Book Value$4.44 per share


Net Income$-50,540,000.00


Market Cap$62.33 million
OptionableNot Optionable

Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) posted its earnings results on Thursday, November, 8th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.79) by $0.03. View Sienna Biopharmaceuticals' Earnings History.

When is Sienna Biopharmaceuticals' next earnings date?

Sienna Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Sienna Biopharmaceuticals.

What price target have analysts set for SNNA?

2 brokerages have issued 1-year price objectives for Sienna Biopharmaceuticals' shares. Their forecasts range from $17.00 to $45.00. On average, they anticipate Sienna Biopharmaceuticals' stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 951.3% from the stock's current price. View Analyst Price Targets for Sienna Biopharmaceuticals.

What is the consensus analysts' recommendation for Sienna Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sienna Biopharmaceuticals.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

News stories about SNNA stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sienna Biopharmaceuticals earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)
  • Mr. John W. Smither, Chief Financial Officer (Age 66)
  • Mr. Majed Kheir, VP of Operations (Age 41)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)
  • Mr. Sean Andrews, Sr. Director of Investor Relations

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Who are Sienna Biopharmaceuticals' major shareholders?

Sienna Biopharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.73%), Northern Trust Corp (0.82%), Geode Capital Management LLC (0.80%), Assenagon Asset Management S.A. (0.33%), Two Sigma Investments LP (0.30%) and SG Americas Securities LLC (0.16%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson, Robert J More, Timothy K Andrews and Todd Harris. View Institutional Ownership Trends for Sienna Biopharmaceuticals.

Which major investors are selling Sienna Biopharmaceuticals stock?

SNNA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A. and Millennium Management LLC. Company insiders that have sold Sienna Biopharmaceuticals company stock in the last year include Robert J More and Todd Harris. View Insider Buying and Selling for Sienna Biopharmaceuticals.

Which major investors are buying Sienna Biopharmaceuticals stock?

SNNA stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, SG Americas Securities LLC, Raymond James & Associates, Dimensional Fund Advisors LP, Paloma Partners Management Co, Rhumbline Advisers, Geode Capital Management LLC and Northern Trust Corp. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $2.9486.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $62.33 million. The company earns $-50,540,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Sienna Biopharmaceuticals employs 47 workers across the globe.

What is Sienna Biopharmaceuticals' official website?

The official website for Sienna Biopharmaceuticals is

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]

MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel